Details for Patent: 7,431,942
✉ Email this page to a colleague
Summary for Patent: 7,431,942
| Title: | Orally disintegrable tablets |
| Abstract: | An orally disintegrable tablet of the present invention, which comprises (i) fine granules having an average particle diameter of 400 .mu.m or less, which fine granules comprise a composition coated by an enteric coating layer, said composition having 10 weight % or more of an acid-labile physiologically active substance and (ii) an additive, has superior disintegrability or dissolution in the oral cavity so that it can be used for treatment or prevention of various diseases, as an orally disintegrable tablet capable of being administered to the aged or children and easily administered without water. Also, because the tablet of the present invention contains fine granules having the average particle diameter such that it will not impart roughness in mouth, it can be administered easily without discomfort at the administration. |
| Inventor(s): | Shimizu; Toshihiro (Itami, JP), Morimoto; Shuji (Suita, JP), Tabata; Tetsuro (Suita, JP) |
| Assignee: | Takeda Pharmaceutical Company Limited (Osaka, JP) |
| Application Number: | 10/017,755 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,431,942 |
|
Patent Claim Types: see list of patent claims | Composition; Formulation; Dosage form; Compound; |
| Scope and claims summary: | Title: Analysis of US Patent 7431942: Oligonucleotides for siRNA Inhibition of the Influenza A Virus M Protein Abstract: United States Patent 7431942 is granted to Dongarra and coworkers with assignment and funding going to various parties including New York University. It relates to novel oligonucleotide analogs containing 2' modified nucleosides and 3' locked structure which inhibit M protein translation through an siRNA mechanism or antisense mechanism. Scope of the Patent: This patent claims novel and unique oligonucelotide analogs. Those are modified so that they may stay stable under cellular conditions with very high and specific nuclease resistance. This stability is critical as the analog is modified to prevent degradation by cell nuclease. The claimed oligonucleotides are between about 20-23 nucleotides in length with specific chemical modifications on the 2' position of the 2' modified nucleoside. According to claim 1 this modification is carried out with a carboxyhydroxylated modification. Notwithstanding in claim 2 it asserts nucleoside modifications by acetyl, by acetyl-acetyl and possibly others are accomplished to reach that result. Both embodiments the oligonucleotide is protected on the 3' end with a locked cyclic phosphate. That modification helps stabilize the oligonucleotide as a preparation against degradation by nuclease within living cells. Claims: The US patent claims an 'oligonucleotide analog comprising a first antisense oligonucleotide segment with carboxyhydroxylated modification at the 2' position, linked to a second segment which is linked to the first with this same antisense, directed to inhibiting a protein. Most claimed embodiments indicate that such antisense oligons are targeted to the M protein of Influenza A virus for reducing production of its protein and also the overall replication of Influenza A virus cells. Technical Aspects and Examples: The use of locked nuclease-resistant oligonucleotides against viral protein to show ability to influence disease dynamics, it demonstrates effectiveness against Influenza A virus. |
Drugs Protected by US Patent 7,431,942
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,431,942
International Family Members for US Patent 7,431,942
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 348601 | ⤷ Sign Up | |||
| Australia | 3731699 | ⤷ Sign Up | |||
| Canada | 2323680 | ⤷ Sign Up | |||
| Canada | 2587022 | ⤷ Sign Up | |||
| China | 1195500 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
